Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Aegis Life","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aegis Life Awarded Grant to Develop DNA-encoded Antibodies Against Infectious Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Aegis Life","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$4.4 million","upfrontCash":"Undisclosed","newsHeadline":"Aegis Life Receives Investment to Continue Development of DNA-Encoded Therapeutic Antibodies Against Infectious Diseases Using the Fusogenix PLV Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Aegis Life

    Menu

    Aegis Life

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Aegis Life

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Aegis Life Receives Investment to Continue Development of DNA-Encoded Therapeutic Antibodies Against Infectious Diseases Using the Fusogenix PLV Platform

              Details:

              The proceeds will support the continuation of the ongoing research collaboration between Aegis Life and Entos Pharmaceuticals, developing novel DNA-based encoded antibody therapeutics against HIV and malaria using the Entos Fusogenix PLV nucleic acid delivery technology.

              Lead Product(s): Undisclosed

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Bill & Melinda Gates Foundation

              Deal Size: $4.4 million Upfront Cash: Undisclosed

              Deal Type: Financing March 19, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Aegis Life

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Aegis Life Awarded Grant to Develop DNA-encoded Antibodies Against Infectious Diseases

              Details:

              The funding will be used to develop the Fusogenix PLV platform for the delivery of DNA-encoded monoclonal antibodies, including HIVV-102, directly inside the patient’s cells for the treatment of infectious diseases such as HIV, influenzas, and malaria.

              Lead Product(s): DNA-encoded Monoclonal Antibody

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Bill & Melinda Gates Foundation

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Funding June 07, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.
              One Pharma aims to be one of the leading generic companies in Europe.
              Post Enquiry
              POST ENQUIRY